Study shows immunotherapy prior to surgery may help destroy high-risk breast cancer
(Yale University) A new study led by Yale Cancer Center (YCC) researchers shows women with high-risk HER2-negative breast cancer treated before surgery with immunotherapy, plus a PARP inhibitor with chemotherapy, have a higher rate of complete eradication of cancer from the breast and lymph nodes compared to chemotherapy alone.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Immunotherapy | Study | Women | Yale